Navigation Links
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy

in all treatment groups. No clinically significant changes in glucose or lipids were seen with nebivolol monotherapy during the study. -- "Addition of the Beta-Blocker Nebivolol to Ongoing Therapy in the Management of Mild-to-Moderate Hypertension" by Alan H. Gradman, MD, Chief, Division of Cardiovascular Diseases, The Western Pennsylvania Hospital. [Poster Presentation, P-383: Monday, May 21 from 12 pm to 1 pm (Riverside Hall)] The blood pressure lowering effects and tolerability of nebivolol added to ongoing antihypertensive therapy in patients was evaluated in this 12-week, randomized, double-blind, placebo-controlled study (n=669). Results indicate that, by comparison to placebo, nebivolol incrementally lowers blood pressure in mild to moderate hypertensive patients when added to ongoing antihypertensive therapy consisting of one or two medications from the following classes: ACE inhibitors, ARBs, or diuretics, with an incidence of reported adverse events similar to placebo. -- "Efficacy of the Novel Beta-blocker Nebivolol in Obese and Non-Obese Hypertensive Patients" by James R. Sowers, MD, Professor of Medicine and Physiology, Director Diabetes and Cardiovascular Center, University of Missouri. [Poster Presentation, P-442: Monday, May 21 from 12 pm to 1 pm (Riverside Hall)] The blood pressure lowering effects of nebivolol was compared in non- obese and obese hypertensive patients, a population that typically has a poorer response to treatment and an increased need for multiple medications. The pooled analysis of three randomized, double-blind, placebo-controlled trials of similar design was stratified by patient obesity status (BMI greater than or equal to 30 kg/m2) at baseline (obese, n=878; non-obese, n=1136). Results suggest that once-
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, ... Boston and their first West Coast location in ... Street in Boston , and will house product ... Southern California office will be located at ... the demands of customers nationwide.  Both new locations will be ...
(Date:9/16/2014)... Sept. 16, 2014  Formex, LLC ("Formex"), ... that Mr. Greg Weilersbacher joined Formex as Director ... Greg Weilersbacher has ... focused expertise in Quality Assurance, Facility Validation, ... Weilersbacher brings to Formex a diverse wealth ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... R.I., Aug. 16, 2011 Medicare Part D beneficiaries ... pay 100 percent of previously subsidized prescription costs, are ... are to switch to more affordable or generic medications, ... concludes. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) The ...
... Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... Phase III clinical studies in patients with refractory chronic ... of the American Medical Association ( JAMA ). ... significant and sustained reductions in uric acid levels along ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:9/16/2014)... Thompson HealthDay Reporter MONDAY, ... strong heart fitness can delay a man,s onset of age-related ... suggests. Blood pressure naturally increases as people grow older ... with strong cardio-fitness don,t start drifting toward high blood pressure ... usually experience the early signs of high blood pressure in ...
(Date:9/16/2014)... A mathematical model that replicates Ebola outbreaks can no ... the current epidemic, finds research conducted by the University ... Warwick Mathematics Institute, developed a model that incorporated data ... , The research, titled Epidemiological Dynamics of Ebola ... when applying the available data from the ongoing 2014 ...
(Date:9/16/2014)... 15, 2014Patients with inoperable, early-stage lung cancer who ... five-year survival rate of 40 percent, according to ... Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. Such a ... conventional RT resulted in poor tumor control for ... an update of RTOG 0236, originally published in ...
(Date:9/16/2014)... YORK, NY (September 16, 2014) The Columbia ... the 2014 Higher Education Excellence in Diversity (HEED) ... and largest diversity-focused publication in higher education. As ... honor recognizing U.S. colleges and universities that demonstrate ... be featured along with 82 other recipients in ...
(Date:9/16/2014)... September 16, 2014. Kessler Foundation researchers have published ... speed in the executive deficits found in individuals ... speed account for executive deficits in multiple sclerosis? ... published online ahead of print on August 18 ... authors are Victoria Leavitt, PhD, of the Manhattan ...
Breaking Medicine News(10 mins):Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Ebola outbreak 'out of all proportion' and severity cannot be predicated 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4
... ... of young adults with disabilities and adjusting to college life. , ... Wellesley, MA (PRWEB) Jan. 26, 2010 ... services, announced that its ChildRC.com web site now features a very informative and exciting ...
... , WASHINGTON , Jan. 26 ... Dateline NBC documentary on patients who have insurance but not adequate ... to deal with the lack of legal accountability for insurers and ... , The nonprofit consumer group called upon Obama to close ...
... , WASHINGTON , Jan. 26 The ... nonpartisan individual membership association of state legislators -- congratulates Pennsylvania ... for filing House Bills 2053 and 2179, which protect the ... Baker and Schroder will hold a joint press conference tomorrow at ...
... NC What does evolution a field that often ... with preventing and treating disease in our lifetime? A lot, ... may soon be tested on evolution in medical entrance and ... A collection of articles in the January 26 issue ...
... European Commission consultation on the EU Clinical Trials Directive, ... proposals by its member organisations for adapting the Directive,s ... treatment. Since the implementation of the Directive ... concerned about the detrimental effect it has had, particularly ...
... 2010 A Universit de Montral research team is developing ... brain to stop eating. "Mice deprived of leptin will not ... around," says Mose Bendayan, a pathology professor at the Universit ... protein extensively. Leptin regulates appetite in mammals and its ...
Cached Medicine News:Health News:ChildRC.com Features “Acclimating To College Life In A Wheelchair” 2Health News:Obama: Make Equal Justice for Patients a State of the Union Pledge & Re-establish White House Office of Consumer Affairs 2Health News:Obama: Make Equal Justice for Patients a State of the Union Pledge & Re-establish White House Office of Consumer Affairs 3Health News:Pennsylvania Legislators Stand for Health Care Freedom 2Health News:Pennsylvania Legislators Stand for Health Care Freedom 3Health News:Pennsylvania Legislators Stand for Health Care Freedom 4Health News:Medical students may soon be tested on evolution 2Health News:Medical students may soon be tested on evolution 3Health News:European Cancer Organization supports a revision of the EU Clinical Trials Directive 2Health News:European Cancer Organization supports a revision of the EU Clinical Trials Directive 3Health News:A gimmick-free weight-loss pill in the works 2
... BD Persist contains 70% alcohol and ... unique polymer base, forming a barrier ... a protective environment for the povidone ... most commonly associated with catheter related ...
... Aplicare's Saturated Swabsticks ... open, single-use foil-laminated pouches. ... is saturated with precisely ... solution. Each package is ...
Triad Plus PVP-I Prep Solution has broad-spectrum germicidal action. Povidone Iodine Solution using an innovative one-piece screw cap, Triad Plus bottles are designed specifically to meet the needs o...
... Aplicare's Saturated Swabsticks are packaged ... Each 4 inch Swabstick is saturated ... solution. Each package is terminally sterilized, ... the patient. It acts as a ...
Medicine Products: